Previous 10 | Next 10 |
-Cohort B of HOPE-3, Phase 3 Clinical Trial Expected to Complete Enrollment in Second Quarter 2024- SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the trea...
Toronto, Ontario--(Newsfile Corp. - February 1, 2024) - Caprock Mining Corp. (CSE: CAPR) (" Caprock " or the " Company ") is pleased to announce the appointment of Mr. Okunola Joshua Aina as its Chief Financial Officer, effective today. Mr. Aina is a senior finance and accounting professional wh...
-Project NextGen Collaboration will Support Capricor’s StealthX™ Exosome Platform and Provide Non-Dilutive Support for Advancement into the Clinic- SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing tra...
Toronto, Ontario--(Newsfile Corp. - January 22, 2024) - Caprock Mining Corp. (CSE: CAPR) (" Caprock " or the " Company ") is pleased to announce that it has entered into an amendment to its option agreement dated January 31 st , 2023 (the " Option Agreement ") setting out the terms of an option t...
Toronto, Ontario--(Newsfile Corp. - January 17, 2024) - Caprock Mining Corp. (CSE: CAPR) (" Caprock " or the " Company ") is pleased to announce a second discovery of lithium-bearing zinnwaldite mineralization (" Area 2 ") in addition to the previously discussed Deer Pond Area within the east...
--Favorable Interim Futility Analysis Results-- --Successful Completion Triggers First Milestone Payment Under U.S. Agreement with Nippon Shinyaku-- --HOPE-3 (Cohort A) Enrollment Complete; Topline Data Expected in the Fourth Quarter of 2024; Cohort B Enrollment Initiated-- ...
Toronto, Ontario--(Newsfile Corp. - November 29, 2023) - Caprock Mining Corp. (CSE: CAPR) ( "Caprock" or the "Company" ) is pleased to announce that following a comprehensive analysis by SGS Natural Resources ( "SGS" ) based in Lakefield, Ontario, the lithium-bearing mineral in samples col...
2023-11-14 20:30:05 ET Capricor Therapeutics, Inc. (CAPR) Q3 2023 Results Conference Call November 14, 2023 04:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Aydin H...
2023-11-14 16:08:08 ET More on Capricor Therapeutics Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy Capricor Therapeutics Q3 2023 Earnings Preview Capricor Therapeutics Q3 2...
-Completed Targeted Enrollment for HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy- -On Track to Report Interim Futility Analysis in Fourth Quarter of 2023; Successful Outcome Would Trigger Milestone Payment to Capricor Under Commercialization and Distribution ...
News, Short Squeeze, Breakout and More Instantly...
Capricor Therapeutics Inc. Company Name:
CAPR Stock Symbol:
NASDAQ Market:
Capricor Therapeutics Inc. Website:
-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility- -FDA Fee...
-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility- -FDA Feedback Supports Requests for a Pre-BLA Meeting and Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting- -Compan...
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and ex...